Narsoplimab for high-risk TMA after bone marrow transplant
Part of Blood & lymphatic clinical trials.
This trial studies the medicine narsoplimab in children who develop a serious complication called HSCT-TMA after a bone marrow transplant. It aims to improve safety and effectiveness for high-risk cases where the condition is ongoing or causing organ problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 28 days old and under 18 years at the time consent is signed
- Have a bone marrow transplant from a donor (an allogeneic HSCT)
- Have HSCT-TMA, shown by low or rapidly falling platelets plus blood changes like hemolysis
- Be considered “high-risk,” such as lasting more than 2 weeks after changing certain anti-rejection medicines, or having kidney/nerve/GI/heart-lung signs
- Not be using eculizumab, ravulizumab, or defibrotide in the 3 months before starting (unless there’s documented failure)
- Not have certain exclusions like STEC-HUS, very low ADAMTS13, pregnancy/breastfeeding, or uncontrolled serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
Hear when a new Thrombotic Microangiopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.